Systolic blood pressure is a major cardiovascular risk factor which is often associated with arterial stiffness. Markers of arterial stiffness, such as pulse pressure and carotid-femoral pulse wave velocity, have been proved independent predictors of cardiovascular risk. Recent evidence suggests that the renin-angiotensin system is involved in the pathogenesis of systolic hypertension and arterial stiffness. Outcome trials have shown impressive cardiovascular protection by reducing systolic blood pressure (BP) with drug treatment. However, in clinical practice systolic hypertension remains largely uncontrolled, first, because systolic BP goal is more difficult to be reached than diastolic and, second, because physicians are often reluctant to intensify treatment in patients with systolic BP close to 150 mmHg. Recent trials have focused on the effects of antihypertensive drugs not only on blood pressure, but also on pulse pressure and pulse-wave velocity. Blockade of the renin-angiotensin-aldosterone system, using angiotensin-converting enzyme inhibitors and more recently angiotensin receptor blockers, has been shown to provide beneficial effects on arterial stiffness that appear to be independent of their antihypertensive effects. Recent outcome trials have shown significant cardiovascular protection with angiotensin receptor blockers. These drugs have an excellent placebolike profile of adverse effects which is maintained when these drugs are combined with low-dose diuretics. Therefore, an angiotensin receptor blocker-based treatment strategy appears to be an attractive and evidencebased approach for the management of systolic hypertension, the reduction of arterial stiffness and the prevention of cardiovascular disease.
Introduction
In the last few decades, there has been great effort and expenditure for the detection and control of hypertension in industrialized countries. [1] [2] [3] However, the levels of hypertension awareness and control are still poor, and elevated BP remains the most common cardiovascular risk factor. [1] [2] [3] [4] For many years, decision making in hypertension was based exclusively on diastolic blood pressure (BP), while only recently it has been recognized that systolic BP may be more important than diastolic. 1, 3, 5 This review presents the risks associated with systolic hypertension, the benefits of its treatment and the rates of its control, the relationship between systolic hypertension, elevated pulse pressure and arterial stiffness, and the effects of the renin-angiotensin system on the pathogenesis of arterial stiffness and systolic hypertension. The effects of antihypertensive drugs on pulse pressure and arterial stiffness and the clinical evidence on the renin-angiotensin system blockade using angiotensin receptor blockers in systolic hypertension are also presented. Articles were identified from the MedLine, using as key words hypertension, systolic blood pressure, treatment, control, prospective studies, clinical trials, meta-analysis, pulse pressure, arterial stiffness, compliance, angiotensin, pulse wave velocity, antihypertensive drugs.
Systolic BP: a powerful modifiable risk factor
Surveys in several populations have shown that systolic BP rises almost linearly between the ages of 30 and 80 years, while diastolic BP rises less steeply until approximately the age of 50-55 years and thereafter tends to decline. 2, 6 This disproportionate rise in systolic BP with ageing results in a high prevalence of isolated systolic hypertension in advanced age. 4 In the Framingham study, 70% of hypertension in the elderly was isolated systolic.
systolic BP with age is a normal and harmless accompaniment of progressive arterial stiffening. 4 Until recently, large outcome trials in hypertension 7 have focused on diastolic BP only, and major worldwide guidelines have traditionally based the classification of the severity of hypertension, the decision to treat and the goal of treatment exclusively on diastolic BP. 8, 9 In recent years, analysis of several major prospective cohort studies, including the Framingham Study, 10 the Multiple Risk Factor Intervention Trial (MRFIT), 11 the Copenhagen City Heart Study 12 and the Honolulu Heart Study, 13 demonstrated that systolic BP is a powerful and independent predictor of cardiovascular and all-cause mortality. More importantly, these studies showed that systolic BP is a stronger risk factor than diastolic BP for coronary disease, stroke and end-stage renal disease. 5 The clinical benefits of lowering systolic BP with antihypertensive treatment in elderly patients with isolated systolic hypertension have been demonstrated in two randomized, placebo-controlled outcome trials, the Systolic Hypertension in the Elderly Program (SHEP) 14 and the Systolic Hypertension in Europe Trial (Syst-Eur) 15 (Table 1) . These studies consistently showed that the treatment of isolated systolic hypertension is one of the most effective interventions in cardiovascular medicine offering impressive cardiovascular protection in terms of both relative and absolute cardiovascular risk reduction (Table 1) A recent meta-analysis of 10 prospective randomized, controlled trials demonstrated the benefits of treatment-induced systolic BP reduction on clinical outcome in patients with isolated systolic or combined systolic and diastolic hypertension. 5 A total of 18 542 patients with mean age 70 years and average follow-up of 3.9 years were included ( Table 2) . Eight trials were conducted in patients with combined systolic and diastolic hypertension and two in isolated systolic hypertension (the above-mentioned SHEP and SystEur trials). The net BP reduction during follow-up in the participants assigned to active antihypertensive treatment compared to those in the control group was 12-13 mmHg for systolic and 5-6 mmHg for diastolic BP. The conclusion of these pooled data is that an average reduction of 12-13 mmHg in systolic BP over 4 years of follow-up is associated with significant reduction in cardiovascular morbidity and mortality (Table 2) .
On the basis of the above evidence on the risks of systolic hypertension and the benefits of its treatment, worldwide guidelines for hypertension management have recently included systolic BP in the classification of the severity of hypertension, the 
Uncontrolled systolic hypertension: a major public health issue
There is increasing awareness that uncontrolled systolic hypertension remains a major public health issue. 5, 6, 16 Despite the increased attention to systolic BP in all hypertension guidelines in the last 10 years, there is convincing evidence suggesting that in clinical practice the control rate for systolic hypertension remains poor. 1, 16 A recent analysis of data from the US National Health and Nutrition Examination Survey investigated the characteristics of untreated or uncontrolled hypertensives. 17 This study showed that most cases of uncontrolled hypertension consist of systolic hypertension with a diastolic BP of less than 90 mmHg. Interestingly, most of the uncontrolled hypertensives in this study had good access to health care and relatively frequent contact with physicians. 17 Recent studies suggest that physicians may not be aggressive enough in their management of hypertension. [18] [19] [20] [21] In a large study, Berlowitz et al 18 showed that an important reason why physicians do not treat hypertension aggressively is because they are willing to accept an elevated systolic BP in their patients. Other studies also showed that primary care physicians are often reluctant to intensify antihypertensive drug treatment in patients with a systolic BP of 150-155 mmHg. 17, 19 The performance of trained general practitioners in reaching the recommended systolic and diastolic BP goals has been evaluated in a recent study. 21 After 6 months of treatment, the majority of patients (85%) had reached the recommended diastolic BP goal, whereas only 50% reached the systolic, and no further improvement in control rates was achieved at 9 months. 21 Despite the poor rates of systolic hypertension control, 31% of patients with uncontrolled systolic BP were on monotherapy and 43% on two drugs, suggesting that the potential of antihypertensive treatment has not been exhausted in this study. 21 Taken together, the above data suggest that there is still some uncertainty among general practitioners about the importance of reducing elevated systolic BP, which may explain, at least in part, the poor levels of control of systolic hypertension in the population.
Physician-related barriers may not be the only reason for the ineffective control of systolic hypertension. This is suggested by the analysis of the findings of the 10 most recent controlled outcome trials of antihypertensive treatment. 22 The average diastolic BP achieved in these trials was below 90 mmHg, whereas systolic BP remained well above 140 mmHg in most of the trials despite the antihypertensive treatment. 22 In other words, approximately 50% of hypertensive patients failed to achieve satisfactory control of systolic BP. The authors of this trial review concluded that even in the context of outcome trials, where patients' compliance and physicians' expertise are ensured, systolic BP control is neither frequently nor easily achieved. 22 A report of the Valsartan Antihypertensive Long-term Use Evaluation trial (VALUE) showed that a systolic BP initiative using intensive up-titration of treatment with systematic use of full doses of multiple drug combinations may improve control rates (68% of participants with systolic BP o140 mmHg). 23 Pulse pressure: an independent cardiovascular risk factor and a marker of arterial stiffness
Owing to the steeper rise of systolic BP compared to diastolic BP with age and the decline in diastolic BP after the 6th decade, pulse pressure (difference between systolic and diastolic BP) increases progressively throughout life and the rate of increase accelerates after the age of 50 years. 24 The attention drawn to the significance of systolic BP elevation led to the realization that pulse pressure may provide additional information, further to that provided by systolic or diastolic BP. 25 Epidemiological and clinical studies suggest that pulse pressure is a powerful and independent predictor of cardiovascular risk. Prospective longitudinal trials in untreated. 26 and treated hypertensives 27 showed that, after adjusting for other risk factors, including systolic and diastolic BP, pulse pressure was significantly and independently associated with the risk for myocardial infarction. Outcome trials in elderly hypertensives such as the Medical Research Council (MRC), 28 the SHEP, 29 the European Working Party on High Blood Pressure in the Elderly (EWPHE) 30 and the Systolic Hypertension in China (Syst-China) 25 have demonstrated that pulse pressure is a stronger predictor for myocardial infarction than systolic BP. In patients with impaired left ventricular function after myocardial infarction, the Survival and Ventricular Enlargement (SAVE) trial 31 again showed that pulse pressure is a powerful independent predictor of recurrent events. A French population study of 19 083 normotensives and hypertensives without cardiovascular disease aged 40-69 years, followed for 20 years, also showed elevated pulse pressure to be a strong predictor of myocardial infarction, particularly in subjects older than 55 years. 32 Finally, in the Framingham study, for any level of systolic BP greater that 120 mmHg, the lower the level of diastolic BP, the greater was the risk for coronary disease. 10 In most of the studies, pulse pressure appeared to be a dominant predictor of coronary events, whereas mean BP was the major independent predictor of cerebrovascular events. 24, 32, 33 However, some studies suggested that elevated pulse pressure may also predict haemorrhagic and atherosclerotic stroke. 34, 35 Elevated pulse pressure has also been associated with several indices of target organ damage such as left ventricular hypertrophy. 31, 36 carotid artery stenosis 35 and microalbuminuria. 37 Most of the studies suggested that a pulse pressure higher than 65 mmHg is associated with a clinically important increase in cardiovascular risk. 24 Pulse pressure values obtained by 24-h ambulatory BP monitoring are more reproducible 38 and more predictive of cardiovascular mortality than office pulse pressure values. 39 Pulse pressure is dependent on left ventricular ejection and on the arterial stiffness predominantly at the level of the aorta and the proximal elastic arteries. 40 Given that left ventricular ejection remains stable or decreases with age, arterial stiffness remains as the major determinant for the increase in pulse pressure with ageing. 40 Therefore, pulse pressure is not simply one more cardiovascular risk factor, such as systolic and diastolic BP, but also a marker of target organ damage at the level of the large arteries. As well as being the result of arterial damage, the rise in systolic BP and pulse pressure increases the fatigue of arterial walls, accelerating the arterial damage and feeding a vicious cycle. 40 Arterial stiffness: a surrogate marker of target organ damage Studies in different populations have shown that hypertension is a major determinant of arterial stiffness. 32, 41 It may be argued that, in hypertensive patients, markers of vascular disease may have strong predictive value, given that hypertension rarely causes morbidity per se, but rather through its deleterious effects on the arteries. It is hoped that, in asymptomatic patients, markers of early vascular disease may help to define subpopulations of high-risk subjects who will benefit from early intervention. These methods are also useful for the comprehensive estimation of the reversal of arterial stiffness with treatment.
A number of methods have been proposed to quantify the arterial stiffness and all of them have limitations. 42 The First Consensus Conference on Arterial Stiffness concluded that pulse wave velocity appears to be the easiest and most practical tool for measurement of arterial stiffness. 42, 43 Pulse wave velocity measures the speed of travel (cm/s) of the pulse along an arterial segment. 44 This is measured as the difference between two sites in the line of pulse travel (eg carotid and femoral artery) and the delay between corresponding points on the pressure or flow wave, which are not influenced by wave reflection. 42 Semiautomated devices that provide reproducible measurements of pulse wave velocity as the mean of several consecutive pressure waveforms taken by pressure transducers are now commercially available. 45 In hypertensive patients, carotid-femoral pulse wave velocity has proved to be an independent predictor of primary coronary events 46 and cardiovascular and all-cause mortality. 47, 48 Therefore, pulse wave velocity appears to be a useful tool for the quantification of target organ damage at the level of the large arteries, as well as for the evaluation of the effects of antihypertensive drugs on the arterial wall.
Renin-angiotensin system and arterial stiffness
Angiotensin II is known to have important local actions on arterial stiffness in regard to fibrosis and collagen synthesis 49 and there is evidence that these effects are mediated through AT 1 receptors. 50 Clinical and experimental studies suggest that the reninangiotensin system may act on the geometry and stiffness of the large artery wall. 44 In a recent review of factors influencing arterial stiffness, Safar and Benetos 44 suggested that the effects of the renin-angiotensin system may clarify several aspects of the pathophysiology of hypertension in the elderly. Accumulating evidence suggests that the influence of gene polymorphisms on arterial stiffness is not limited to a single gene, but is influenced by the interaction of various genes. 44, 51 However, it has been suggested that the AT 1 receptor gene polymorphism A1166C may be the most important candidate to consider. 44 The influence of the AT 1 receptor gene polymorphism appears to be combined with that of several other gene polymorphisms, specifically linked to cardiovascular ageing or act on vasoconstrictive mechanisms, to determine arterial stiffness. 44, 51 Some evidence suggests that genes regulating the renin-angiotensin system may not only influence the effect of age but also the effect of renin-angiotensin system blockade on arterial stiffness by influencing the accumulation of collagen within the arterial wall. 44 The presence of the C or T alleles of the AT 1 receptor gene polymorphism has been associated with a steeper increase in pulse pressure with age, than in non-C, non-T population. 52 Furthermore, hypertensive subjects with the C allele have been shown to exhibit a greater effect on pulse wave velocity compared to other allele groups for the same degree of chronic angiotensin-converting enzyme (ACE) inhibition. 53 These actions of the renin-angiotensin system and its blockade appear to be independent of effects on BP.
Effects of antihypertensive drugs on arterial stiffness
Given the prognostic significance of markers for arterial stiffness, recently published studies of antihypertensive drug efficacy have focused on treatment effects not only on BP but also on pulse pressure and pulse wave velocity. [54] [55] [56] [57] It should be mentioned that any antihypertensive agent is expected to reduce arterial stiffness, given that BP reduction per se unloads the stiff components of the arterial wall such as collagen. 43 However, it seems likely that pharmacologic treatment is able to improve arterial stiffness beyond BP reduction. 43 Whether some antihypertensive drug classes are advantageous in improving arterial stiffness remains controversial. 43 A review of long-term trials in hypertensive patients assessing the effects of different drugs on arterial stiffness concluded that ACE inhibitors, calcium antagonists and diuretics are equally effective in reducing arterial stiffness. 43 An older meta-analysis of seven randomized trials showed no difference between the effects of ACE inhibitors, diuretics, beta-blockers and dihydropyridines in improving pulse wave velocity. 58 However, there was a trend for the dihydropyridines to be less effective, which might be attributed to activation of the sympathetic nervous system known to occur with these drugs. 43 A double blind, crossover, placebo-controlled study that compared four classes of antihypertensive drugs showed that an ACE inhibitor, a calcium antagonist and a diuretic reduce central aorta systolic pressure, whereas a beta-blocker did not. 59 These data clearly show that antihypertensive drugs with similar effects on brachial pressure may differ in their effects on central aortic pressure. 59 The nonselective beta-blocker propranolol and the selective beta 1 -blocker atenolol have been shown to enhance pulse wave reflection from the arterial tree and, therefore, to increase aortic augmentation index resulting in a lesser decline of central aortic pressure compared to other drugs. 42, 60 However, there is evidence that other more lipophilic betablockers differ in their ancillary and vasodilating properties that affect pulse wave reflection. [60] [61] [62] Accumulating evidence from recent clinical trials suggest beneficial effects of ACE inhibitors on arterial stiffness. [63] [64] [65] [66] [67] A small placebo-controlled trial showed that 3-months treatment with the ACE inhibitor perindopril increased brachial artery compliance and decreased pulse wave velocity. 63 These favourable effects on forearm arterial haemodynamics returned toward baseline values 4 weeks after treatment withdrawal. 63 A large multicentre uncontrolled study in 1703 hypertensive subjects showed that the antihypertensive effect of perindopril administered for 6 months was accompanied by a significant decrease in carotid-femoral pulse wave velocity. 64 Furthermore, in a recently published, randomized, parallel group placebo-controlled trial that compared an ACE inhibitor, an angiotensin receptor blocker, two calcium antagonists and two beta-blockers in 168 hypertensives, the ACE inhibitor appeared to be the only compound that increased flow-mediated dilation. 65 A double-blind randomized study in 471 hypertensive patients followed for 1 year showed that, for the same diastolic BP reduction, a low-dose combination of the ACE inhibitor perindopril with the diuretic indapamide decreased pulse wave velocity to a similar degree as the beta-blocker atenolol, but was more effective in attenuating carotid-wave reflections. 66 This study showed that with atenolol the principal factor modulating systolic BP reduction was mean BP, whereas the ACE inhibitor/ diuretic combination induced significantly greater reduction of central systolic BP. The authors concluded that the advantageous haemodynamic effects of the ACE inhibitor/diuretic combination reflect changes of wave reflections issued from distal arterial and arteriolar territory, where the ACE inhibitors are known to improve vessel wall structure. 67 Further to the important local actions of angiotensin II on arterial stiffness via the AT 1 receptor, 50 there are additional reasons to believe that blocking of the renin-angiotensin system using angiotensin AT 1 receptor blockers (ARBs) can regulate vascular function. The ARB irbesartan has been shown to exert anti-inflammatory properties in patients with early 68 or advanced atherosclerosis, 69 whereas candesartan has also been shown to reduce inflammatory cytokines and to reverse endothelial dysfunction. 70 Therefore, it appears that blocking of the renin-angiotensin system with ARBs may be beneficial in reversing arterial remodelling and atherogenic processes.
Evidence from recent clinical trials suggests that ARBs can favourably affect markers of arterial stiffness. Trials in hypertensive patients have shown that treatment with several ARBs reduces BP as well as pulse pressure. [54] [55] [56] [57] Studies using measurements of carotid-femoral pulse wave velocity also demonstrated improvement of arterial stiffness with ARBs. 50, 54, 71, 72 More importantly, these beneficial effects of ARBs on the large artery wall appear to be independent of their effects on BP. 50, 71, 72 One small randomized study showed that, for the same BP reduction, an ARB might be more efficacious than a diuretic in decreasing arterial stiffness and arterial wave reflection. 73 A study in hypertensive subjects showed an ACE inhibitor to be superior to an ARB or a calcium antagonist in decreasing pulse wave velocity, 74 whereas another study in elderly hypertensives demonstrated greater reductions in pulse pressure and pulse wave velocity with an ARB compared to an ACE inhibitor or a calcium antagonist. 75 Interestingly, it has been suggested that ACE inhibitors and ARBs may have additive effects in reducing arterial stiffness. 76 It is clear that large comparative trials or meta-analyses are required to show the optimal treatment in terms of reversing arterial stiffness.
Blocking of the renin-angiotensin system using angiotensin receptor blockers: clinical evidence
Outcome trials have demonstrated significant improvement of prognosis using ARBs in patients with heart failure, [77] [78] [79] myocardial infarction, 80,81 left ventricular hypertrophy 82 and diabetic nephropathy 83, 84 or microalbuminuria. 85 A recent metaanalysis of 29 prospective randomized outcome trials including 162 341 hypertensives found no significant differences in cardiovascular disease protection between regimens based on ACE inhibitors, calcium antagonists, diuretics or beta-blockers. 86 However, greater reduction in the risk of stroke, heart failure and major cardiovascular events was noted in four trials with ARBs compared to control regimens 86 (Table 3 ). This advantage of ARBs in preventing disease may, at least in part, be attributed to greater BP reduction (2/1 mmHg greater in ARB treated compared to control group). 86 However, specific protective effects of ARBs, for example, through their beneficial actions on the arterial wall, cannot be excluded.
The above-mentioned outcome data have established the value of ARBs in cardiovascular medicine and the 2003 European guidelines (ESH/ESC), 1 the WHO-ISH guidelines 3 and the US JNC-7 report, 2 all recommend the use of these drugs as first-line treatment in the management of hypertension, together with diuretics, ACE inhibitors, calcium antagonists and beta-blockers. As a result of the wide availability and the low cost of diuretics, these drugs have been placed one step forward in the ESH/ESC and the WHO/-ISH guidelines and are recommended 'for the most' when there are no compelling indications for other drug classes. 1, 3 Several trials in elderly patients with isolated systolic hypertension showed that ARBs effectively reduce systolic BP with a lesser decrease in diastolic BP, resulting thereby in substantial reduction of pulse pressure. [87] [88] [89] [90] It is important to note that these beneficial effects are achieved with a placebo-like tolerability. [88] [89] [90] A substudy of the Losartan Intervention for End point Reduction trial (LIFE) in 1326 subjects with isolated systolic hypertension and left ventricular hypertrophy showed that, for the same BP reduction, the ARB losartan was better tolerated and more effective than the beta-blocker atenolol in regressing left ventricular hypertrophy and in 92, 93 and irbesartan has been shown to be more effective than the calcium antagonist amlodipine. 94 ACE inhibitors also have a strong database of outcome trials showing remarkable cardiovascular protection in patients with hypertension, or with renal, cardiac or cerebrovascular disease. 86 ACE inhibitors and ARBs are blockers of the same system (renin-angiotensin) and therefore are expected to have important similarities in their antihypertensive effects. However, there are data supporting the view that these drug classes have differences in their antihypertensive effects, which are clinically important. 95 First, studies have shown additive antihypertensive effects with combined ARB and ACE inhibition. [96] [97] [98] [99] Second, it has been shown that some hypertensive patients show good BP response to ACE inhibitors but not to ARBs, or the opposite. [100] [101] [102] These observations suggest that there are important differences in the mechanisms of antihypertensive action between ACE inhibitors and ARBs, which are not only of theoretical but also of clinical significance. 95, 100, 102 ARBs seem to provide a more complete and specific blockade of the renin-angiotensin system than ACE inhibitors, which may be advantageous in terms of organ protection and disease prevention.
BP lowering is regarded as a major component of the benefit conferred by antihypertensive drug treatment. 86 Randomized comparative studies using 24-h ambulatory BP monitoring suggested that, within the ARB drug class, BP lowering efficacy may not be invariably homogeneous between agents. For example, studies have shown candesartan 103 and telmisartan 104 to be more efficacious in reducing BP than losartan. Furthermore, irbesartan was found superior than both losartan and valsartan in terms of duration and overall magnitude of the antihypertensive effect. 105, 106 Angiotensin receptor blocker-based combinations in the management of systolic hypertension Recent outcome studies have taught us that in order to reach the recommended systolic BP goal more than 50% of hypertensive subjects will require combination pharmacotherapy with two or more drugs.
1,2 The JNC-7 recommends the initiation of therapy with two drugs in most patients with stage-2 hypertension or with BP that is more than 20/ 10 mmHg (systolic/diastolic) above goal. 2 The 2003 European guidelines (ESH-ESC) also endorse the initiation of treatment with two drugs. 1 In order to reduce prescription costs and improve compliance, guidelines recommend that fixed combination drugs should be preferred. 1, 2 ARBs are unique antihypertensive drugs because they provide cardiovascular and renal protection 86 with an excellent placebo-like tolerability. On the other hand, thiazide-type diuretics have been the basis of antihypertensive therapy in most outcome trials [1] [2] [3] 86, 107 and have a strong evidence base in systolic hypertension. 1, 14 Diuretics have been shown to be superior to beta-blockers in reducing BP and preventing cardiovascular events. 108 Therefore, the combination of an ARB with a low-dose thiazide diuretic offers an attractive evidence-based treatment. Meta-analysis of 43 controlled trials showed that ARB monotherapy induces average systolic and diastolic BP reductions of 10.4-11.8 and 8.2-8.9 mmHg, respectively, whereas combined treatment of ARB with hydrochlorothiazide induces greater BP reductions of 16.1-20.6 and 9.9-13.6 mmHg, respectively. 109 For instance, a fixed combination of the ARB irbesartan with low-dose hydrochlorothiazide has been shown to achieve goal BP in 65-75% of hypertensive patients. 110, 111 The greater BP reductions achieved in systolic compared to diastolic BP results in parallel reduction of pulse pressure with both the ARB monotherapy and the ARB-hydrochlorothiazide combinations. 109 It is important to note that this combination maintains the unique advantage of the ARB class, with regard to the excellent placebo-like profile of adverse effects, 110, 112 and even ameliorates the dose-related biochemical abnormalities associated with hydrochlorothiazide alone. 112 Calcium antagonists have been shown to provide cardiovascular protection and are regarded as firstline drugs in hypertension [1] [2] [3] 86, 107 and specifically systolic hypertension. 1, 15 Interestingly, a substudy of the INSIGHT trial showed that patients with isolated systolic hypertension were more responsive to treatment with long-acting nifedipine than subjects with ordinary hypertension. 113 Clinical trials have shown additive antihypertensive effects and favourable tolerability with the combination of an ARB with a calcium antagonist. 99, 114, 115 In hypertensive patients uncontrolled on ARB monotherapy, similar additive antihypertensive effects were achieved with a calcium antagonist or a thiazide-diuretic. 99 In elderly patients with isolated systolic hypertension, one study also showed additive antihypertensive affects with the ARB-calcium antagonist combination and fewer side effects were observed compared with each of the monotherapies. 114 ACE inhibitors have also been shown to provide additive antihypertensive effects when combined with ARBs in short-term studies. [96] [97] [98] [99] One randomized study showed that, in patients uncontrolled on ARB monotherapy, the magnitude of the additive effect of a thiazide-diuretic or a calcium antagonist was greater than that of an ACE inhibitor. 99 At present no outcome study in hypertension has assessed the usefulness of the ARB-ACE inhibitor combination in preventing cardiovascular events. Until more data become available, this combination should be regarded as second line in the management of hypertension. 1 Triple antihypertensive drug therapy is often needed in order to achieve the optimal control of BP, particularly in patients with diabetes or renal disease, but also in many patients with uncomplicated stage 2 or 3 essential hypertension.
1 This is more the case for systolic hypertension, which, as discussed above, appears to be more difficult to control than diastolic hyperleusion. 22 It should be remembered that in the outcome trials in hypertension, the benefits of antihypertensive treatment in preventing cardiovascular disease and death have been achieved using triple combinations in about 30% of patients. 1, 7, 82, 107 In order to manage a pathophysiologically multifactorial disease, such as hypertension, a multimechanistic therapeutic approach is required. 116 Thus, a logic approach expected to achieve the maximal antihypertensive effect would be to combine drugs with different mechanisms of action. 116 ARBs, calcium antagonists and thiazide-diuretics are different approaches for BP lowering, in terms of their mode of antihypertensive action. Calcium antagonists have been shown to provide additive antihypertensive effects with ARBs 99, 114, 115 but also with thiazide-diuretics. 117 Thus, an ARB-diuretic combination administered together with a calcium antagonist appears to provide an attractive triple treatment for systolic hypertension with additive BP lowering effects and multidimensional actions.
Despite the frequent use of triple drug combinations in the outcome trials and in clinical practice, 1 clinical trials providing formal comparisons of such combinations have not been reported. In the WHO-ISH guidelines the important issue of the lack of randomized outcome trials to guide selection of optimal combinations in terms of prevention of mortality and morbidity is discussed. In line with their preference for diuretics, the JNC-7 and the WHO-ISH recommend the use of a low-dose diuretic in most of the combinations because of their benefits in terms of enhanced efficacy of other drug classes, good tolerability and low cost. 1, 2 It is clear, however, that more clinical research on the efficacy and tolerability of antihypertensive drug combinations is needed.
Conclusions
Systolic BP is a major risk factor for cardiovascular morbidity and mortality, which is often associated with increased pulse pressure and arterial stiffness. In clinical practice, systolic hypertension remains largely uncontrolled, first, because systolic BP goal is more difficult to be reached than diastolic and, second, because physicians are often reluctant to intensify treatment in patients with systolic BP close to 150 mmHg. An ARB-based treatment strategy appears to be an attractive and evidence-based approach for the management of systolic hypertension, the reduction of arterial stiffness and the prevention of cardiovascular disease.
